Plenary Session

View Top 200 Chart

Back to Rankings Page

Health & Fitness
**Plenary Session**

Dr Prasad on medicine, oncology, & health policy.
Host: Vinay Prasad, MD MPH from University of California San Francisco.
Tweet your feedback to @Plenary_Session or e-mail plenarysessionpodcast@gmail.com

Latest Episodes:

5.41 - Michael Putman MCW debates me on recent policy Qs Feb 16, 2023

Show notes

Mike Putman, asst prof. EBM Rhematologist debates me on value of boosters, observational studies and more.

Sensible Med Superbowl Plenary Session Crossover Feb 13, 2023

Show notes

A new podcast feed called Sensible Medicine is up; here is a sample of what we have to offer

5.39 - Sotorasib and Codebreak 200 Feb 10, 2023

Show notes

I destroy the trial. Bad control arm. Informative Censoring. No OS gain. Authors DOWNPOWERED TRIAL. Fishy PFS. Fishy HRQoL. This trial should be in trash can.

Myeloma Twitter Just Makes Things Up - Lessons for All Oncologists & Expertise Jan 22, 2023

Show notes

I annotate an online case discussion; Every decision is not based in evidence. Madness

5.37 - Keynote Lecture on Physician Burnout Jan 15, 2023

Show notes

This lecture on Burnout will not be like any other you have heard

5.36 - ASH UPDATE #4 - GEM CESAR Dec 30, 2022

Show notes

I break down the GEM CESAR trial K, R, D, Pom, Dara, Dex, R, and Auto and all before you actually have cancer What a crazy trial!

5.35 - ASH Update #3 - the Ascent Trial Dec 29, 2022

Show notes

This uncontrolled trial of Dara-KRD claims to be looking for cure; Unfortunately, the PI has not thought through what that would look like, and accordingly all the claims are incorrect. Moreover the primary endpt is negative. Sad day for oncology

5.34 - ASH Update #2 - ALPINE - Zanibrutinib vs Ibrutinib - Deconstructed Dec 24, 2022

Show notes

Sample size games, primary endpoint, head to head trials in oncology Rate this podcast on itunes Coming next is Triangle trial

5.33 USC Grand Rounds Hematology Dec 23, 2022

Show notes

Grand rounds on heme and heme malignancies given 12/16 at University of Southern California (some parts removed) More ASH coming soon

5.32 - ASH Update #1 - Talquetamab NEJM Dec 11, 2022

Show notes

Is it acceptable to take someone with myeloma who has gotten just 2 regimens and put them on a phase 1? VP says hell no.

Our TOPPODCAST Picks

Follow Us

Stay Connected

Related Podcasts

Links

Stay Connected